'Rare' Brain Disorder May Be More Common Than Thought, Say Mayo Clinic Scientists

 ‘Rare' Brain Disorder May Be More Common Than Thought, Say Mayo Clinic Scientists

JACKSONVILLE, Fla.--(BUSINESS WIRE)--A global team of neuroscientists, led by researchers at Mayo Clinic in Florida, have found the gene responsible for a brain disorder that may be much more common than once believed. In the Dec. 25 online issue of Nature Genetics, the researchers say they identified 14 different mutations in the gene CSF1R that lead to development of hereditary diffuse leukoencephalopathy with spheroids (HDLS). This is a devastating disorder of the brain's white matter that leads to death between ages 40 and 50. People who inherit the abnormal gene always develop HDLS.

 

The finding is important because the researchers suspect that HDLS is more common than once thought. According to the study's senior investigator, neurologist Zbigniew Wszolek, M.D., a significant number of people who tested positive for the abnormal gene in this study had been diagnosed with a wide range of other conditions. These individuals were related to a patient known to have HDLS, and so their genes were also examined.

"Because the symptoms of HDLS vary so widely -- everything from behavior and personality changes to seizures and movement problems -- these patients were misdiagnosed as having either schizophrenia, epilepsy, frontotemporal dementia, Parkinson's disease, multiple sclerosis, stroke, or other disorders," says Dr. Wszolek. "Many of these patients were therefore treated with drugs that offered only toxic side effects.

"Given this finding, we may soon have a blood test that can help doctors diagnose HDLS, and I predict we will find it is much more common than anyone could have imagined," he says.

Dr. Wszolek is internationally known for his long-term effort to bring together researchers from around the world to help find cases of rare brain disorders and discover their genetic roots.

Dr. Wszolek's interest in HDLS began when a severely disabled patient came to see him in 1995 and mentioned that other members of his family were affected. He was able to definitively diagnose the disease upon autopsy of the patient because of changes in the white matter. Until then, only one family in Sweden had been diagnosed with HDLS.

Dr. Wszolek began to search for other cases, and his Mayo Clinic colleague, Dennis Dickson, M.D., a pathologist, recalled seeing such changes in a brain while he was in training. Dr. Dickson located two more cases in Florida and Michigan, and Dr. Wszolek began to talk about HDLS at every research presentation he made throughout the world. He soon had brain samples from Norway, the United Kingdom, and Canada, and from different areas in the U.S. He and his team of investigators and collaborators have since published numerous studies describing the disorder and have held five international meetings on HDLS.

In this study, which included 38 researchers from 12 institutions in five countries, the study's first author, Rosa Rademakers, Ph.D., led the effort to find the gene responsible for HDLS. Her laboratory studied DNA samples from 14 families in which at least one member was diagnosed with HDLS and compared these with samples from more than 2,000 disease-free participants. The gene was ultimately found using a combination of traditional genetic linkage studies and recently developed state-of-the art sequencing methods. Most family members studied -- who were found to have HDLS gene mutations -- were not diagnosed with the disease, but with something else, thus emphasizing the notion that HDLS is an underdiagnosed disorder.

The CSF1R protein is an important receptor in the brain that is primarily present in microglia, a type of immune cells. "We identified a different CSF1R mutation in every HDLS family that we studied," says Dr. Rademakers. "All mutations are located in the kinase domain of CSF1R which is critical for its activity, suggesting that these mutations may lead to deficient microglia activity. How this leads to the loss of brain cells in HDLS patients is not yet understood, but we now have an important lead to study."

"With no other disease have we found so many affected families so quickly," says Dr. Wszolek. "That tells me this disease is not rare, but quite common."

He adds, "It is fantastic that you can start an investigation with a single case and end up, with the help of many hands, in what we believe to be a world-class gene discovery."

The study was funded by a Mayo benefactor and the Mayo Foundation. Additionally, Mayo Clinic in Florida is a Morris K. Udall Parkinson's Disease Research Center of Excellence supported by the National Institute of Neurological Disorders and Stroke.

About Mayo Clinic

Mayo Clinic is a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. For more information, visit www.mayoclinic.org/about/ and www.mayoclinic.org/news.

 

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.